Genentech USA
Manufacturing · United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
United StatesWebsite
www.genentech-access.comRevenue
$17.8 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Genentech USA
Genentech Access Solutions provides access and reimbursement support for healthcare professionals to assist their patients in obtaining necessary medications. The company offers a range of products including treatments for oncology, ophthalmology, and rheumatology, such as ACTEMRA, Avastin, and Herceptin. Their services include coverage assistance, reimbursement resources, and product distribution information. Genentech aims to help patients focus on their health by facilitating access to their prescribed medicines.Explore more
Genentech USA Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Genentech USA your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Genentech USA, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Genentech USA had a recent Job posting/layoffs
Check out if Genentech USA is spiking on competitors!
Earning: See what the market has to say on Genentech USA recently announced quarterly report
Funding: Get notified immidiatlly once Genentech USA has new funding data
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Genentech USA
Check if Genentech USA has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Genentech USA launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at Genentech USA
Find 3 more new buyers
Compare Similar Companies to Genentech USA
Compare insights from companies similar to Genentech USA, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Genentech USA is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Genentech USA is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Genentech USA.
Genentech USA Tech Stack
A closer look at the technologies used by Genentech USA
See more technologies
Genentech USA News & Media
Genentech’s Vabysmo Improved Vision in Underrepresented Populations With Diabetic Macular Edema (DME) in a First-Of-Its-Kind Study
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline one-year results from the open-label, single-arm Phase IV ELEVATUM study evaluating Vabysmo® (faricimab-svoa) for the treatment of diabetic macular edema (DME) in people from racial and ethnic groups that are often underrepresented in clinical trials. Initial data from 124 participants in the United States showed that after one year of treatment witFDA Approves Ocrevus Zunovo™ as the First and Only Twice-a-Year 10-Minute Subcutaneous Injection for People With Relapsing and Progressive Multiple Sclerosis
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the United States Food and Drug Administration (U.S. FDA) has approved Ocrevus Zunovo™ (ocrelizumab & hyaluronidase-ocsq) for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). Ocrevus Zunovo is the first and only twice-a-year, healthcare professional (HCP)-administered approximately 10-minute subcutaneousFDA Approves Genentech’s Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Tecentriq Hybreza™ (atezolizumab and hyaluronidase-tqjs), the first and only PD-(L)1 inhibitor for subcutaneous (SC), under the skin injection for patients in the United States. Tecentriq Hybreza can be injected subcutaneously over approximately seven minutes, compared with 30-60 minutes for standard IV iNew Data for Genentech’s Susvimo Demonstrates Sustained Efficacy in Two Serious Diabetic Eye Conditions
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today two-year data from the Phase III Pagoda and Pavilion studies evaluating Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema (DME) and diabetic retinopathy (DR), respectively, the two leading causes of vision loss in adults with diabetes. Susvimo is the first and only refillable eye implant that provides continuous delivery of a cus
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Genentech USA
Sign Up For FreeTo access detailed company insights
Genentech Access Solutions provides access and reimbursement support for healthcare professionals to assist their patients in obtaining necessary medications. The company offers a range of products including treatments for oncology, ophthalmology, and rheumatology, such as ACTEMRA, Avastin, and Herceptin. Their services include coverage assistance,... Read More
